Open Longevity Science

2012, 6 : 56-63
Published online 2012 June 29. DOI: 10.2174/1876326X01206010056
Publisher ID: TOLSJ-6-56

Immunotherapy of Immunosenesence; Who, How and When?

Sheila Govind , Antonio Lapenna , Pierre Olivier Lang and Richard Aspinall
Cranfield Health Cranfield University, Bedfordshire MK43 0AL, UK.

ABSTRACT

Major changes in social welfare, economic conditions and medical knowledge over the last 60 years have pro-duced a demographic shift in the population. More individuals are living longer, and in a decade there will be more people over 65 than infants under 5 for the first time in history. Taking the analysis beyond mere numbers reveals that older indi-viduals are now physically more active than their forebears and travel more widely. This provides a greater opportunity for encountering infectious agents which could present a considerable problem. Older individuals are more susceptible to infection and do not respond as well as younger people to vaccination because of an age related decline in immunity, a state which has been termed immunosenesence. This decline is not uniform and some older individuals show a greater de-cline in their immune response than others. In this review we have sought to consider who are the ‘at risk’ individuals, how they might best be treated and when.

Keywords:

Immunosenescence, rejuvenation, reversion, healthy ageing, frailty.